Cerevel Therapeutics (CERE)
(Delayed Data from NSDQ)
$41.90 USD
+1.59 (3.94%)
Updated Jul 15, 2024 04:00 PM ET
After-Market: $41.90 0.00 (0.00%) 5:50 PM ET
2-Buy of 5 2
C Value F Growth B Momentum D VGM
Cerevel Therapeutics Holdings, Inc. (CERE) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$43.40 | $45.00 | $31.00 | 7.67% |
Price Target
Based on short-term price targets offered by 10 analysts, the average price target for Cerevel Therapeutics Holdings, Inc. comes to $43.40. The forecasts range from a low of $31.00 to a high of $45.00. The average price target represents an increase of 7.67% from the last closing price of $40.31.
Analyst Price Targets (10)
Broker Rating
Cerevel Therapeutics Holdings, Inc. currently has an average brokerage recommendation (ABR) of 2.80 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 10 brokerage firms. The current ABR compares to an ABR of 2.64 a month ago based on 11 recommendations.
Of the 10 recommendations deriving the current ABR, one is Strong Buy, representing 10% of all recommendations. A month ago, Strong Buy represented 18.18%.
Broker Rating Breakdown
![Broker Rating Visualization](https://widget3.zacks.com/images/charts/bar/brokerage/bar/CERE.png)
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 1 | 2 | 2 | 2 | 2 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 9 | 9 | 9 | 9 | 9 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 2.80 | 2.64 | 2.64 | 2.64 | 2.64 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
6/17/2024 | Not Identified | Not Identified | Hold | Hold |
6/17/2024 | Cantor Fitzgerald & Co | Charles C Duncan | Hold | Hold |
6/3/2024 | Piper Sandler | David Amsellem | Hold | Hold |
4/1/2024 | Cowen & Co. | Joseph Thome | Hold | Hold |
2/16/2024 | Mizuho SecuritiesUSA | Graig Suvannavejh | Hold | Hold |
12/22/2023 | Wells Fargo Securities | Mohit Bansal | Strong Buy | Strong Buy |
12/7/2023 | H.C. Wainwright & Co. | Douglas Tsao | Strong Buy | Hold |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 2.80 |
ABR (Last week) | 2.64 |
# of Recs in ABR | 10 |
Average Target Price | $43.40 |
LT Growth Rate | NA |
Industry | Medical - Drugs |
Industry Rank by ABR | 157 of 252 |
Current Quarter EPS Est: | -0.58 |